MA55140A - Méthode sûre et efficace de traitement de la rectocolite hémorragique avec un anticorps anti-il12/il23 - Google Patents
Méthode sûre et efficace de traitement de la rectocolite hémorragique avec un anticorps anti-il12/il23Info
- Publication number
- MA55140A MA55140A MA055140A MA55140A MA55140A MA 55140 A MA55140 A MA 55140A MA 055140 A MA055140 A MA 055140A MA 55140 A MA55140 A MA 55140A MA 55140 A MA55140 A MA 55140A
- Authority
- MA
- Morocco
- Prior art keywords
- ultracolitis
- antibody
- safe
- treating
- effective method
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862735501P | 2018-09-24 | 2018-09-24 | |
| PCT/IB2019/058098 WO2020065532A1 (fr) | 2018-09-24 | 2019-09-24 | Méthode sûre et efficace de traitement de la rectocolite hémorragique avec un anticorps anti-il12/il23 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA55140A true MA55140A (fr) | 2021-09-29 |
| MA55140B1 MA55140B1 (fr) | 2023-09-27 |
Family
ID=88507038
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA55140A MA55140B1 (fr) | 2018-09-24 | 2019-09-24 | Méthode sûre et efficace de traitement de la rectocolite hémorragique avec un anticorps anti-il12/il23 |
Country Status (1)
| Country | Link |
|---|---|
| MA (1) | MA55140B1 (fr) |
-
2019
- 2019-09-24 MA MA55140A patent/MA55140B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MA55140B1 (fr) | 2023-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3883606A4 (fr) | Méthode sûre et efficace de traitement de la rectocolite hémorragique avec un anticorps anti-il12/il23 | |
| EP3687563A4 (fr) | Méthode sûre et efficace de traitement de lupus avec un anticorps anti-il12/il23 | |
| EP2975055A4 (fr) | Anticorps anti-c5 et méthode de prévention et de traitement de maladies liées au complément | |
| EP3706794A4 (fr) | Méthode sûre et efficace de traitement de l'arthrite psoriasique par un anticorps spécifique anti-il23 | |
| EP3838289A4 (fr) | Anticorps anti-tigit et ses utilisations | |
| EP3589660A4 (fr) | Anticorps anti-pd-l1 et utilisations associées | |
| MA52962A (fr) | Méthodes de traitement du cancer avec des anticorps bispécifiques anti-cd3xmuc16 et des anticorps anti-pd-1 | |
| MA54562A (fr) | Méthode sûre et efficace de traitement du lupus avec un anticorps anti-il12/il23 | |
| EP3395359A4 (fr) | Méthode de prévention ou de traitement de la thrombose aiguë et chronique | |
| EP3395353A4 (fr) | Méthode de prévention ou de traitement de la neuropathie diabétique et des affections associées | |
| EP3778649A4 (fr) | Méthode et composition de traitement de tumeurs | |
| EP3427678A4 (fr) | Dispositif médical et méthode de traitement | |
| EP3683580A4 (fr) | Stylo de détection électronique et méthode de détection précoce du nombre de semaines de grossesse | |
| IL285401A (en) | Anti-clec2d antibodies and methods of use thereof | |
| MA51899A (fr) | Inhibiteurs de btk et de leurs mutants | |
| EP3877037A4 (fr) | Méthode et système de traitement de neurorégénération | |
| EP3920693A4 (fr) | Anticorps anti-nme et méthode de traitement du cancer ou de métastases cancéreuses | |
| EP3465349A4 (fr) | Procédé amélioré de modélisation et de simulation par ordinateur de photorésines à développement de ton négatif | |
| EP3794345A4 (fr) | Méthode associée à l'agoniste sigma-1 optimisé de sélection et de traitement de répondeur | |
| FR3026745B1 (fr) | Methode d'analyse et interpretation automatisee d'un antibiogramme | |
| EP3765277A4 (fr) | Système et méthode de fabrication de prothèses | |
| MA41462A (fr) | Méthode de traitement de maladies | |
| EP3883607A4 (fr) | Procédé sûr et efficace de traitement du psoriasis avec un anticorps spécifique anti-il-23 | |
| EP3887822A4 (fr) | Méthode de détection de cancer et/ou de tuberculose | |
| IL281233A (en) | Automated generation and analysis of organoids |